[Saccharomyces cerevisiae] A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome.

   Abstract

   Background: We aimed to evaluate clinical symptoms in subjects with irritable bowel syndrome receiving Saccharomyces  

  cerevisiae in a randomized double-blind placebo-controlled clinical trial.

   Methods : Overall, 179 adults with irritable bowel syndrome (Rome III criteria) were randomized to receive once daily 500 mg of       

  Saccharomyces cerevisiae, delivered by one capsule (n = 86, F: 84%, age: 42.5 ± 12.5), or placebo (n = 93, F: 88%, age: 45.4

  ± 14) for 8 weeks followed by a 3-week washout period. After a 2-week run-in period, cardinal symptoms (abdominal pain / 

  discomfort, bloating/distension, bowel movement difficulty) and changes in stool frequency and consistency were recorded daily 

  and assessed each week. A safety assessment was carried out throughout the study.

   Results : The proportion of responders, defined by an improvement of abdominal pain/discomfort, was significantly higher (p =  

  0.04) in the treated group than the placebo group (63% vs 47%, OR = 1.88, 95%, CI: 0.99–3.57) in the last 4 weeks of   

  treatment. A non-significant trend of improvement was observed with Saccharomyces cerevisiae for the other symptoms. 

  Saccharomyces cerevisiae was well tolerated and did not affect stool frequency and consistency.

   Conclusion : Saccharomyces cerevisiae is well tolerated and reduces abdominal pain/discomfort scores
  without stool modification. Thus, Saccharomyces cerevisiae may be a new promising candidate for improving
  abdominal pain in subjects with irritable bowel syndrome.

제목 

A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome

[출처 : G. Pineton de Chambrun et al. / Digestive and Liver Disease 47 (2015) 119–124]